Nonalcoholic Fatty Liver Disease

Reviewing Treatment for Nonalcoholic Fatty Liver Disease

Reviewing Treatment for Nonalcoholic Fatty Liver Disease

By

A range of pharmacologic agents have a potential role in the management of NAFLD.

Intrahepatic Lipid Content Reduced With Physical Activity in NAFLD

Intrahepatic Lipid Content Reduced With Physical Activity in NAFLD

For patients with nonalcoholic fatty liver disease and underlying metabolic disorders, physical activity is associated with a reduction in intrahepatic lipid content and markers of hepatocellular injury.

Greater Awareness of NAFLD, NASH in Diabetes Needed

Greater Awareness of NAFLD, NASH in Diabetes Needed

By

Clinicians must be aware of the overlap between nonalcoholic fatty liver disease and nonalcoholic steatohepatitis and other metabolic disorders.

Nonalcoholic Fatty Liver Disease Risk Higher With Hypothyroidism

Nonalcoholic Fatty Liver Disease Risk Higher With Hypothyroidism

By

Lower thyroid function was associated with a 1.24-fold higher risk for nonalcoholic fatty liver disease.

Saroglitazar May Help Treat Nonalcoholic Fatty Liver Disease

Saroglitazar May Help Treat Nonalcoholic Fatty Liver Disease

By

Treatment with saroglitazar was linked to sonographic improvement in fatty liver.

Estrogen Deficiency in Women Linked to Nonalcoholic Fatty Liver Disease

Estrogen Deficiency in Women Linked to Nonalcoholic Fatty Liver Disease

Duration of estrogen deficiency in women with nonalcoholic fatty liver disease may be more likely to have severe fibrosis.

MRI vs Transient Elastography for Identifying Fibrosis, Steatosis in NAFLD

MRI vs Transient Elastography for Identifying Fibrosis, Steatosis in NAFLD

Researchers found better diagnostic performance for MRI- vs transient elastography-based measurements for liver fibrosis and steatosis.

Metabolic Profile Worse in Type 2 Diabetes Patients With NAFLD

Metabolic Profile Worse in Type 2 Diabetes Patients With NAFLD

For obese patients with type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) is associated with an unfavorable metabolic profile.

Nonalcoholic Fatty Liver Disease Linked to Worse Outcomes in STEMI

Nonalcoholic Fatty Liver Disease Linked to Worse Outcomes in STEMI

Patients with moderate to severe fatty liver disease may be more likely to have impaired myocardial perfusion.

Sex-Specific Differences in NAFLD Risk Examined

Sex-Specific Differences in NAFLD Risk Examined

Differences in hepatic fat oxidation may explain higher prevalence, risk for nonalcoholic fatty liver disease in men.

Exercise Dose, Intensity Didn't Affect Liver Fat Reductions

Exercise Dose, Intensity Didn't Affect Liver Fat Reductions

In randomized trial, there was no difference in efficacy of liver fat reduction by aerobic exercise dose or intensity.

Endocrine-Disrupting Chemicals May Cause Fatty Liver

Endocrine-Disrupting Chemicals May Cause Fatty Liver

By

Exposure to low doses of hormone-disrupting chemicals may alter the liver genome and function, thereby increasing susceptibility to obesity.

Restricting Fructose Consumption May Reduce Liver Fat Accumulation

Restricting Fructose Consumption May Reduce Liver Fat Accumulation

By

Restricting intake of fructose may prevent accumulation of fat in the liver of obese children.

Improving Detection of Nonalcoholic Fatty Liver Disease

Improving Detection of Nonalcoholic Fatty Liver Disease

New imaging techniques show promise for diagnosing NAFLD.

Imaging Technique May Help Detect Nonalcoholic Fatty Liver Disease in Children

Imaging Technique May Help Detect Nonalcoholic Fatty Liver Disease in Children

By

MRI-based technique may aid in detection, evaluation of the disease.

NAFLD in Teens Tied to Childhood Adiposity Trajectories

NAFLD in Teens Tied to Childhood Adiposity Trajectories

Adiposity at age 3 years linked to diagnosis and severity of hepatic steatosis in late adolescence.

Fatty Liver Disease May Be Less Common in Type 1 Diabetes

Fatty Liver Disease May Be Less Common in Type 1 Diabetes

Patients with type 1 diabetes may be less likely to develop fatty liver disease.

Sign Up for Free e-Newsletters



CME Focus